Trial · NCT05952882
Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility
NCT05952882, Phase 3, Unknown, Mỹ Đức Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility. Trials, record NCT05952882. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05952882
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility
- NCT number
- NCT05952882
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 188 participants, estimated
- Lead sponsor
- Mỹ Đức Hospital
- Conditions
- Polycystic Ovary Syndrome, Obesity, Infertility, Female
- Interventions
- Liraglutide + Metformin, Metformin
- First posted
- 2023-07-19
- Last updated
- 2023-10-23
Source ClinicalTrials.gov
Registered outcomes60
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Absolute Body Weight (BW) | 12 weeks of treatment | Treatment impact on change in body weight after 12 weeks of treatment. |
| Primary | Change in Percent Body Weight | 12 weeks of treatment | Treatment effect on reducing body weight expressed as percent body weight loss from baseline |
| Secondary | Body Mass Index (BMI) | 12 weeks of treatment | Treatment effect in reducing body mass |
| Secondary | Abdominal Adiposity (Waist Circumference [WC]) | 12 weeks of treatment | Treatment effect on loss of waist circumference (abdominal adiposity) with drug treatment |
| Secondary | Waist-to-Hip Ratio (WHR) | 12 weeks of treatment | Change in central adiposity with treatment as measured by waist-to-hip ratio. A reduction in ratio indicates a decrease in truncal fat. |
| Secondary | Waist-to Height Ratio [WHtR] | 12 weeks of treatment | Treatment effect on loss of central adiposity as determined by Waist-to Height Ratio. The lower the ratio indicates less abdominal adiposity. |
| Secondary | Total Fat Mass Evaluated by BIA | 12 weeks of treatment | Treatment effect on reduction of fat mass (kg) |
| Secondary | Total Body Fat (%) by BIA (Bioelectrical Impedance Analysis) machine | 12 weeks of treatment | Treatment effect on reduction of percent body fat by BIA |
| Secondary | Visceral Fat Level (VFL) | 12 weeks of treatment | Treatment effect on reduction of visceral fat level by BIA |
| Secondary | Total lean body mass | 12 weeks of treatment | Treatment impact on total lean body mass |
1 to 10 of 60Source ClinicalTrials.gov
See all 60 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers27
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05952882
GET https://conductscience.org/api/trials/v1/NCT05952882/registered?page=2